Evidence map›Paper›PMID 40321802›Full record

ArticleInternational journal of nanomedicine2025

The Nb

Shuying He, Yuerong Lv, Zixian Gao, Liang Peng

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shuying He *Department of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou city, Guangdong Province, People's Republic of China.
Yuerong Lv *Department of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou city, Guangdong Province, People's Republic of China.
Zixian Gao *Department of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou city, Guangdong Province, People's Republic of China.
Liang PengDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou city, Guangdong Province, People's Republic of China.ORCID 0000-0001-7021-4651

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The incidence of metabolic dysfunction-associated steatohepatitis (MASH) is increasing because people's dietary habits are dominated by high caloric intake and sedentary lifestyles, leading to the accumulation of lipid, reactive oxygen species (ROS) and inflammation. However, treating MASH remains a challenge. Methods: Two-dimensional (2D) niobium carbide (Nb Results: Nb Conclusion: The Nb

Indexed as

AntioxidantsFatty LiverNon-alcoholic Fatty Liver DiseaseReactive Oxygen SpeciesAnimalsAnti-Inflammatory AgentsDisease Models, AnimalHepatocytesLipid MetabolismMacrophagesMaleMiceMice, Inbred C57BLOxidative StressRAW 264.7 CellsAnti-Inflammatory AgentsAntioxidantsReactive Oxygen Speciesmacrophagemetabolic dysfunction-associated steatohepatitisNb4C3ROS scavenging

Identifiers

PMID40321802
PMCPMC12050042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.